Cancer registry software is a programmed tool of a directory that creates and maintains end-to-end reporting of cancer incidences. It is majorly used to get an overview of certain cases while investigating cancer and its causes. According to Market Research Future, the global cancer registry software market reached $56.4 Million in 2022 and is predicted to attain a CAGR of 10.7% during the forecast period, 2022-2027
Extraordinary breakthroughs and penetrations of science and technology are evolving radically and restructuring the practice of medicine. Aging population, growing middle spending abilities on healthcare, the burden of chronic disease is transforming the patient needs. However, these factors are stimulating new demands dedicated to innovation and access to advanced tools that deliver reliable patient data and comprehensive report of every stage in treatment.
Novel technologies such as predictive modeling for medical procedures are set to flourish owing to growing investment in RD activities in the field of clinical and molecular data. Growing trend of using data analytics to create reference case study for futuristic clinical operations is likely to propel the global cancer registry software market.
Industry leaders are keenly focusing on the development of convenient and accessible solutions for handling critical data related to cancer. Some of the leading players contributing with their product and services include McKesson Corporation, Electronic Registry Systems, Inc., IBM, C/Net Solutions, Himagine Solutions Inc, Rocky Mountain Cancer Data Systems, Ordinal Data Inc, Conduent Inc, Elekta AB (PUB), and Onco, Inc.
The global Cancer Registry Software Market Size is broadly segmented based on the factor such as type, deployment model, database, functionality, and end-user.
The type segment is bifurcated into standalone software and integrated software.
Based on the deployment model, the global cancer registry software market is divided into on-premise and cloud-based.
Similarly, the database type segment is classified into public and commercial.
On the basis of functionality, the global cancer registry software market is segmented into product outcome evaluation, patient care management, medical research, clinical studies, and reporting to federal regulations.
Moreover, the end-user segment is diversified into hospitals, government organizations, medical practitioners, pharmaceutical, research centers, medical device companies, and biotechnology.
Geographically, the Americas is expected to influence the global cancer registry software market owing to the growing focus on high-tech product development, growing investment for RD in region. As per National Cancer Institute, approximately 1,735,350 new cases of cancer were registered in the US, in 2022.
Europe ranks second after the Americas owing to funding availability and existence of robust research and academic institutes in the region. The European cancer registry software market is anticipated to register a considerable growth during the forecast period.
Moreover, emerging pharmaceutical industry due to low manpower cost and favorable trade conditions in developing markets such as India and China are foreseen to speed up the growth of cancer registry software market in Asia Pacific. A growing number of cancer patients in these regions in contrast to the escalating population makes it mandatory to keep a track on every cancer patient and their diagnostic data.
The Middle East Africa has the least contribution in the global cancer registry software market and is anticipated to see a moderate growth owing to rising government initiatives for healthcare sectors.
Market Research Future (MRFR), enable customers to unravel the complexity of various industries through Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research Consulting Services.
Market Research Future (part of Wantstats Research and Media Private Limited),
99 Hudson Street,5Th Floor, New York,
New York 10013